GSK is a global biopharma company focused on infectious diseases, HIV, respiratory, immunology, and oncology, operating through its vaccines business and specialty medicines including its ViiV Healthcare HIV joint venture.
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Common
2,006.3M
Pre-funded warrants
0.0M
Options
0.0M
RSUs
33.5M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
2,039.8M
Cap table as of 2025-12-31.
Price history
Loading GSK daily closes…
Loading price history…
Next catalyst
Midazolam (MDZ) · Now - Nov 16, 2026 Now · Phase 1 · Malaria, Falciparum
Recently reported
Ris-Rez Phase 3Positive · 2026-10-26
ARTEMIS-011 · relapsed or refractory osteosarcoma
Primary: Independent Review Committee (IRC)-assessed progression-free survival (PFS) — Median PFS was 5.5 months with Ris-Rez versus 1.4 months with chemotherapy (HR, 0.33; 95% CI, 0.20-0.55; p<0.0001), after a median follow-up of 7.1 months
· Ris-Rez reduced the risk of disease progression or death by 67% compared with chemotherapy
· Grade 3 or higher treatment-related adverse events occurred in 93% of patients receiving Ris-Rez at the 12 mg/kg dose and 83% in those receiving chemotherapy
· Treatment-related adverse events led to discontinuation in 4% of patients receiving Ris-Rez and 2% of patients receiving chemotherapy
· Ris-Rez 12.0 mg/kg every 3 weeks versus gemcitabine 1,000 mg/m2 on days 1 and 8 plus docetaxel 75 mg/m2 on day 8 every 3 weeks
· The late-breaking results were presented during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 and will support a regulatory submission by Hansoh in China
Safety: Grade 3 or higher treatment-related adverse events in 93% on Ris-Rez versus 83% on chemotherapy, the most common being haematologic events; discontinuations due to treatment-related adverse events 4% versus 2%; safety findings consistent with prior findings in this tumour type
Primary: Confirmed objective response rate (ORR) in the Phase Ib dose-optimisation portion of EMBOLD PanTumour-101 (NCT06551142) in relapsed extensive-stage small cell lung cancer — Confirmed ORR of 61% at the 8 mg/kg dose (n=11/18; 95% CI: 35.7-82.7), compared with 32% at the 6 mg/kg dose (n=7/22; 95% CI: 13.9-54.9)
· 50 ES-SCLC patients who had received a median of two prior therapies
· Median follow-up of 100.5 days
· Data supported selection of the 8 mg/kg dose being evaluated in the global phase III EMBOLD SCLC-301 study
Safety: Manageable across both dose levels: grade 3 or higher treatment-related adverse events in 42% of patients at 8 mg/kg and 15% at 6 mg/kg, most commonly haematological; interstitial lung disease in 1 out of 50 patients (2%, grade 2)
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Approved US Oct 2025 (EU, Japan) in combination after two or more prior lines; in other markets after one or more prior lines. Only anti-BCMA ADC accessible in community settings.
Nucala
Approved · ActiveModality: biologic
Target IL-5
Indications
Severe eosinophilic asthma(Approved)
Eosinophilic granulomatosis with polyangiitis (EGPA)(Approved)
Hypereosinophilic syndrome(Approved)
Chronic rhinosinusitis with nasal polyps(Approved)
Status note Named among five key assets with major approvals in 2025; indication not stated in excerpts.
Blujepa
Approved · ActiveModality: small molecule
Target bacterial type II topoisomerase
Indications
Uncomplicated urinary tract infection(Approved)
Status note Named among five key assets with major approvals in 2025; indication not stated in excerpts.
Status note Phase 2 registrational AZUR-1 in curative-intent dMMR/MSI-H rectal cancer (Breakthrough + Fast Track + National Priority Voucher). AZUR-2 in colon cancer ongoing.
Status note Pivotal Phase 3 data reported; next-generation low-carbon propellant formulation.
Risvutatug rezetecan
Phase 3 · Active
Target B7-H3
Indications
Extensive-stage small cell lung cancer (2L/3L)(Phase 3)
Status note Pivotal trial started in 2L/3L ES-SCLC.
Efimosfermin
Phase 3 · Active
Target FGF21
Indications
MASH-related fibrosis(Phase 3)
Status note Pivotal trial started for fibrosis caused by MASH.
Arexvy
Approved · ActiveModality: vaccine
Indications
RSV(Approved)
Status note Expanded approvals in 2025.
Shingrix
Approved · ActiveModality: vaccine
Indications
Shingles(Approved)
Status note Expanded approvals in 2025.
Per-asset detail extracted from the 20-F filed 2026-03-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (163 as sponsor, 124 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.